Theranostics · Literature Radar
Ga-68 PSMA-11 / -617 PET imaging — selection, biochemical-recurrence detection, intra-prostatic mapping. Curated daily from Europe PMC (PubMed + PMC + preprints) and OpenAlex — free-full-text link on each open-access paper.
Farag A, Felder C, Hussey D, Mirshahvalad SA et al.
BackgroundPSMA PET/CT using ¹⁸F‑DCFPyL and ⁶⁸Ga‑labelled tracers is central to prostate cancer staging, but ⁶⁸Ga‑PSMA may show reduced sensitivity and quantitative accuracy, partly due to respiratory …
Ploysongsang SS, Kongthanarat Y, Jirotmontree T, Panpimanmas S et al.
Metastasis of prostate cancer to the appendix is exceedingly rare. We can find only 11 cases reported in the world English literature. Their diagnoses were made postoperatively after presenting sympto…
Gühne F, Küppers A, Kühnel C, Seifert P et al.
BackgroundPSMA PET/CT plays an important role in biochemically recurrent prostate cancer (BCR-PCa). In general, PET/CT is performed as a limited or true whole-body examination. The majority of PET/CT …
Wagle A, Satapathy S, Suresh A, Sarkar SR et al.
68Ga-PSMA-11-PET/CT is widely used for staging prostate cancer but may also detect nonprostatic malignancies owing to prostate-specific membrane antigen (PSMA) expression in tumor neovasculature. Here…
Zhang W, Dong Y, Xu L, Liao P et al.
PurposeThis study was designed to investigate the detection rate and tumor uptake of 18F-AlF-NOTA-De-FAPI PET/CT in newly diagnosed high-risk prostate cancer (PCa), compared with 68Ga-PSMA-11 and 18F-…
Ahmadi M, Rezaei N, Taheri F, Samadi MH et al.
We report a case of a 60-year-old man with biopsy-proven prostate adenocarcinoma who underwent 99mTc-PSMA scintigraphy during evaluation for potential 177Lu-PSMA radioligand therapy. The scan demonstr…
Ebrahimifard A, Bagheri S, Wang Q, Hojjat Shamami A et al.
This retrospective analysis interrogates the value of a multimodal biomarker paradigm to characterize molecular and clinical responses to [²²⁵Ac]Ac-PSMA-617-targeted α-therapy (TAT) in cohorts of heav…
Lin BH, Zeng CL, Wu XH, Gao RC et al.
ObjectivesTo investigate the performance of ⁶⁸Ga-PSMA-11 PET/CT for diagnosing tumor thrombus (TT) and predicting response to pembrolizumab and axitinib in renal cell carcinoma (RCC) with TT.MethodsWe…
Schmidt CJ, Bernhardt M, Kristiansen G, Gaertner FC et al.
ObjectivesTo compare the segment-based diagnostic performance of multiparametric magnetic resonance imaging (mpMRI), Gallium-68-prostate-specific membrane antigen-positron emission tomography/computed…
Sun B, Werner D, Ni J, Weidle S et al.
Prostate-specific membrane antigen (PSMA)-targeted α-therapy holds promise for the treatment of prostate cancer but has increased side effects compared with therapy using β-emitting PSMA ligands. This…
Kassar M, Hu J, Rauscher I, Gomes CV et al.
Large language models show great promise for clinical decision support but generally lack medical imaging integration. Therefore, vision-language models have been proposed, but there is little evidenc…
Edouard L, Papillon L, Ferrer L, Godbert Y et al.
PurposeMetastatic castration-resistant prostate cancer (mCRPC) remains incurable despite recent therapeutic advances. [¹⁷⁷Lu]Lu-PSMA RLT (lutetium-177 labelled prostate-specific membrane antigen radio…
Cuzzocrea M, Pecoraro G, Iacovitti CM, Martinello C et al.
Background/Objectives: Lutetium-177 prostate-specific membrane antigen radioligand therapy ([¹⁷⁷Lu]Lu-PSMA-RLT) is an effective treatment for patients with metastatic castration-resistant prostate can…
Kishan AU, Wilhalme H, Felix C, Enke J et al.
The phase 2 randomized LUNAR trial previously demonstrated that neoadjuvant ¹⁷⁷Lu-PNT2002 before stereotactic body radiotherapy (SBRT) significantly improved progression-free survival (PFS) in patient…
Lepor H, Vargas HA, Tafa M, Wysock JS et al.
PurposeThe optimal timing to obtain the initial PET-PSMA imaging study when disease recurrence is suspected following RP is controversial.Methods24 subjects with new onset of BCR following RP were enr…
Diamand R, Artigas C, Peltier A, Van Eycken M et al.
PurposeEquivocal Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions carry an intermediate risk of clinically significant prostate cancer (csPCa). We evaluated the diagnostic value…
Lichtman-Mikol S, Lang JM, Nagar H, Zuhour R et al.
IntroductionProstate cancer (PCa) is the most commonly diagnosed cancer in men worldwide. A rising proportion of men present with de novo metastatic disease, a state associated with poor survival outc…
Schötz E, Ufton D, Weindler J, Schmidt M et al.
ObjectivePSMA tumor volume (PSMA-TV) is increasingly investigated as a quantitative biomarker for treatment assessment and prognostic stratification in metastatic castration-resistant prostate cancer …
Kitajima K, Naka S, Hatano K, Uemura M et al.
ObjectiveThe performance of ¹⁸F-labeled prostate-specific membrane antigen (¹⁸F-PSMA-1007) positron emission tomography/computed tomography (PET/CT) and bone scintigraphy (BS) for detecting bone metas…
Belliveau C, Saad F, Duplan D, Petit C et al.
BackgroundProstate-specific membrane antigen positron emission tomography (PSMA-PET) improves lesion detection, leading to treatment intensification via PSMA-guided radiotherapy (PSMAgRT), but its imp…
Hong CM, Moradi Tuchayi A, Abtahi M, Nwihim S et al.
PurposeMultiple prostate-specific membrane antigen (PSMA) PET tracers are used for patient selection in radioligand therapy (RLT). This study compared treatment response to RLT across different PSMA t…
Sridhar A, Behiri N, Klubo-Gwiezdzinska J.
The incidental thyroid uptake of radiolabeled ligands used in positron emission tomography/computed tomography (PET/CT) targeting cell-surface proteins is observed in up to 6% of all scans. While diff…
Hekimsoy T, Sauter AP, Tauber R, Horn T et al.
This retrospective analysis aimed to evaluate the diagnostic performance of ¹⁸F-flotufolastat PET/MRI for the detection of clinically significant prostate cancer (csPCa). The primary objective of the …
Çelik A, Gültekin A, Şengöz T, Şimşek FS et al.
ObjectiveThis study aimed to investigate the prognostic value of volumetric parameters derived from staging Ga-68 PSMA PET/CT imaging in predicting biochemical recurrence (BCR) among prostate cancer p…
Karimzadeh A, Fütterer C, Hansen K, Coban Ö et al.
¹⁷⁷Lu-prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is an established treatment for metastatic castration-resistant prostate cancer, though responses vary. A prognosti…
Pires M, Gutschmayer S, Bergalla E, Chauvie S et al.
The purpose of this study was to develop and validate lesion identification in oncologic nuclear imaging (LION), an open-source PET-only tumor segmentation pipeline for [¹⁸F]FDG and prostate-specific …
Gómez Rivas J, Fernández Hernández L, Turpin L, Peyrottes A et al.
PurposeTo examine the gap between evidence-based indications for PSMA PET/CT and real-world access in prostate cancer, with a focus on European implementation and country-specific experience from Spai…
Mattana F, Luzzago S, Dragonetti V, Kasivisvanathan V et al.
PurposeOligometastatic disease (OMD) represents an intermediate disease state between localized and metastatic prostate cancer (PCa), where patients may still benefit from curative treatments. The pre…
Kaya EM, Esen Akkaş B, Uluçay M, Aghazada F et al.
ObjectiveTo investigate the effect of the biopsy-to-imaging interval on intraprostatic maximum standardized uptake value (SUVmax) and adverse pathology (AP) prediction in patients with low-to-intermed…
Noamen H, Bekkhoucha A, Bernard Tessier A, Trabelsi K et al.
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) has emerged as a major therapeutic advance in metastatic castration-resistant prostate cancer (mCRPC), The phase III VISION…
Laschena L, Pecoraro M, Messina E, Bicchetti M et al.
PurposeTo compare the diagnostic performance of MRI using the PI-RR scoring system and PSMA-PET/CT in detecting prostate cancer (PCa) local recurrence after radical prostatectomy (RP), and to identify…
Akgüner G, Güleşen Aİ, Yıldırım ÖA.
Background/Objectives: Depth of prostate-specific antigen (PSA) response is prognostic in metastatic hormone-sensitive prostate cancer (mHSPC), and the SUVmax of the most avid lesion is a readily avai…
Gill SM, Yousaf F, Razi M, Akhtar S.
Prostate cancer (PCa) is the most common cancer and third leading cause of mortality in males. Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed by 100- to 100…
Le Guévelou J, Bauckneht M, Soeterik TFW, Scheltema M et al.
ContextAlthough prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is commonly used for both initial staging and restaging at biochemical recurrence fo…
Sayman HB, Aras O, Hekim MV, Sağlam K et al.
PurposeTo evaluate the feasibility, safety, and preliminary efficacy of systemic targeted alpha therapy with [²²⁵Ac]-PSMA in patients with recurrent high-grade glioma (HGG). Glioblastoma multiforme (G…
Gossili F, Harving F, Petersen AC, Madsen C et al.
PurposeProstate-specific membrane antigen (PSMA) PET has emerged as a sensitive imaging modality for prostate cancer (PC), but its role in intraprostatic tumour localisation relative to multiparametri…
Seront E, Lhommel R, Van Maanen A, Pasoglou V et al.
The introduction of immune checkpoint inhibitors (ICIs) combined with tyrosine kinase inhibitors has improved outcomes in metastatic clear cell renal cell carcinoma (ccRCC). However, conventional imag…
Schmidt CJ, Reichert T, Gaertner FC, Kreppel B et al.
PurposeMultiparametric MRI and PSMA PET/CT have improved prostate cancer detection and targeting. While MRI-guided biopsy is well established, data on the procedural safety and patient-reported outcom…
Villalba-Meneses CP, Noboa AP, Villegas-Paredes VM.
Prostate cancer is among the most frequently diagnosed malignancies worldwide. In high-risk disease, conventional imaging underestimates nodal and skeletal extent, so treatment intent may be defined o…
Aleenajitpong N, Cochran RL, Mercaldo S, Kaur H et al.
BackgroundMultiparametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) PET are increasingly used for pretreatment staging of prostate cancer, but their incremental prognostic value for pr…
Kleiburg F, Heijmen L, Witteveen A, van Duuren K et al.
BackgroundTraditional metastatic burden classifications in metastatic hormone-sensitive prostate cancer (mHSPC) rely on conventional imaging using CHAARTED criteria. As PSMA PET/CT is increasingly use…
Hu J, Chunyu H, Yang Y, Song Y et al.
PurposeTo develop and externally validate a preoperative ¹⁸F-PSMA-1007 PET/MR model for biochemical recurrence (BCR) after radical prostatectomy and assess its incremental prognostic value beyond clin…
Huang C, Jin L, Sun Y, Wu M et al.
PurposeMultiparametric MRI (mpMRI)-ultrasound (US) fusion biopsy misses 8%-20% of clinically significant prostate cancer (csPCa), leaving a detection gap that prostate-specific membrane antigen (PSMA)…
Sherif Z, Sherif K, Forbes A.
Multiparametric MRI and prostate-specific membrane antigen positron emission tomography (PSMA PET) have become established imaging modalities for the diagnosis and staging of prostate cancer. Dual-lay…
Alayed Y, Loblaw A, Mendez LC, Correa RJM et al.
ARGOS-CLIMBER is a phase 1/2 trial evaluating PSMA PET and MRI guided prostate SABR with a simultaneous boost to intraprostatic and nodal disease in men with unfavourable intermediate and high-risk pr…
Vetrone L, Prosperi E, Prosperi E, Vasuri F et al.
PurposeHepatocellular carcinoma (HCC) is a heterogeneous malignancy with limited diagnostic and prognostic tools beyond conventional imaging modalities such as CT and ceMRI. Prostate-specific membrane…
Hernández-Alejo A, González-Ballesteros X, Maya-García H, Salinas-Rodríguez D et al.
Ling SW, de Jong A, Gorris M, Segbers M et al.
Most patients with metastatic castration-resistant prostate cancer (mCRPC) do not benefit from treatment with immune checkpoint inhibitors targeting programmed cell death (ligand) 1 (PD-(L)1). Radiati…
Hayk Petrosyan, Marine Mnatsakanyan, Isabella Karapetyan, A. Manukyan et al.
Background: 18F-prostate-specific membrane antigen (18F-PSMA-1007) is a recognized positron emission tomography (PET) radiotracer commonly used for prostate tumor imaging due to its excellent tumor-to…
Hadaschik B, Sartor O.
Theranostics, particularly PSMA-targeted imaging and radiopharmaceutical therapy, is rapidly transforming the field of urooncology. This article reviews the clinical integration of PSMA PET/CT in diag…
Lindenberg L, Huang E, Ulaner GA, Patel KR et al.
In this article, we assess histologically validated quantitative parameters on ¹⁸F-piflufolastat (¹⁸F-DCFPyL) prostate-specific membrane antigen (PSMA) PET and identify thresholds for differentiating …
Liepe K, Hoang TM, Dietrich I, Piechota HJ et al.
ObjectivesThe aim of this study was to examine the combined influence of initial PSA level (iPSA) and ISUP grade on the detection rates of [99mTc]Tc-PSMA SPECT/CT in patients undergoing primary stagin…
Civan C, Karpinski MJ, Darr C, Selvamoorthy T et al.
Background and objectiveProstate-specific membrane-antigen positron emission tomography (PSMA-PET) detects distant metastases in more than half of patients with increasing prostate-specific antigen de…
Amorelli F, Plaza P, Natali A, Blanco JS et al.
Biochemical recurrence (BCR) after radical prostatectomy (RP) frequently occurs despite negative conventional imaging, making salvage treatment decisions challenging. We evaluated the impact of 18F-DC…
Mok A, Chen J, Russon A, Mansberg V et al.
A 77-year-old man was referred for an 18F-DCFPyl PET/CT scan for staging of prostate cancer. The scan demonstrated an incidental intensely avid brain lesion in the right frontal lobe. Subsequently, a …
Bihani Pokharel, Mingtao Feng, Yuechao Yang, Zhe Qi et al.
Malignant brain tumors have high morbidity and poor prognosis. Prostate-specific membrane antigen (PSMA) has emerged as a promising vascular biomarker in this setting, particularly in gliomas and brai…
Grün A, Partyka A, Galler M, Schlomm T et al.
IntroductionTo provide a detailed analysis regarding survival, local control and toxicity of nodal/bone oligo-recurrent prostate cancer identified and treated with PSMA-PET/CT and robotic SBRT using a…
Sai H, Kuruma H, Okada A, Enei Y et al.
BackgroundNeuroendocrine differentiation in advanced prostate cancer is associated with aggressive behavior, resistance to androgen receptor pathway inhibition, and altered tracer expression. Although…
Agritelley MS, Hao B, Hill S, Zhou B et al.
Indeterminate bone lesions (IBLs) on prostate-specific membrane antigen (PSMA) PET/CT are common and pose a diagnostic dilemma with important management implications. There is currently no clear conse…
van Mossel S, van der Velden KJM, Kleiburg F, Bosch D et al.
IntroductionRecent study results of our group demonstrated that [¹⁸F]PSMA-1007 (PSMA) PET/CT outperforms PSA response in predicting overall survival in metastatic castration-resistant prostate cancer …
Showing the 60 most recent of 206 papers in this topic.Browse every paper →
Request brochure
Tell us who you are and we’ll send the full product brochure to your institutional email after a quick review. We respond within one working day (Mon–Fri, 9:30–18:30 IST).
A Saxsons sales engineer will review your request and send the brochure to your institutional email within one working day. You may receive a verification call before processing.
